Scarica l'app Stockscreener
87.78
0.63%
0.555
Arcellx Inc Borsa (ACLX) Ultime notizie
(ACLX) Proactive Strategies - Stock Traders Daily
arcellx CFO Michelle Gilson sells $156,508 in shares By Investing.com - Investing.com Canada
arcellx CFO Michelle Gilson sells $156,508 in shares - Investing.com India
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? - MSN
First Turn Management LLC Makes New Investment in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat
Arcellx, Inc. (NASDAQ:ACLX) Position Reduced by Victory Capital Management Inc. - MarketBeat
First Week of January 2025 Options Trading For Arcellx (ACLX) - Nasdaq
Arcellx, Inc. (NASDAQ:ACLX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Arcellx (NASDAQ:ACLX) Shares Down 6.4%What's Next? - MarketBeat
Paradigm Biocapital Advisors LP Acquires Significant Stake in Ar - GuruFocus.com
Perceptive Advisors LLC Adjusts Position in Arcellx Inc - GuruFocus.com
arcellx director Kavita Patel sells $159,495 in stock - Investing.com
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice - Yahoo Finance
FMR LLC Adjusts Stake in Arcellx Inc - GuruFocus.com
arcellx CFO Michelle Gilson sells $1.24 million in stock By Investing.com - Investing.com South Africa
Arcellx director Kavita Patel sells $5.97 million in stock - Investing.com
arcellx CFO Michelle Gilson sells $1.24 million in stock - Investing.com
Arcellx director Kavita Patel sells $5.97 million in stock By Investing.com - Investing.com UK
US Bancorp DE Acquires 2,851 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World
Arcellx, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights - Defense World
Objective long/short (ACLX) Report - Stock Traders Daily
Piper Sandler Forecasts Strong Price Appreciation for Arcellx (NASDAQ:ACLX) Stock - Defense World
Arcellx Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
HC Wainwright Has Optimistic Outlook of Arcellx Q3 Earnings - Defense World
Analyst Expectations For Arcellx's Future - Benzinga
Arcellx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Arcellx (NASDAQ:ACLX) Hits New 1-Year High on Analyst Upgrade - Defense World
Arcellx earnings missed by $0.14, revenue fell short of estimates - Investing.com UK
HC Wainwright Estimates Arcellx's Q3 Earnings (NASDAQ:ACLX) - MarketBeat
HC Wainwright Boosts Arcellx (NASDAQ:ACLX) Price Target to $95.00 - Defense World
Needham & Company LLC Reiterates Buy Rating for Arcellx (NASDAQ:ACLX) - Defense World
Morgan Stanley Forecasts Strong Price Appreciation for Arcellx (NASDAQ:ACLX) Stock - Defense World
Bank of America Raises Arcellx (NASDAQ:ACLX) Price Target to $100.00 - Defense World
Arcellx : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q) - Marketscreener.com
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights - BioSpace
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar? - MSN
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Arcellx stock soars to all-time high of $97.61 amid robust growth - Investing.com India
Arcellx (NASDAQ:ACLX) Hits New 52-Week High on Analyst Upgrade - MarketBeat
Arcellx (ACLX) Releases Clinical Data from Phase 1 and iMMagine-1 Studies for Multiple Myeloma Patients On November 5, 2024, Arcellx, Inc. (NASDAQ: ACLX) made public an abstract containing fresh clinical data from its Phase 1 and iMMagine-1 - Defense World
Arcellx price target raised to $106 from $81 at Morgan Stanley - Yahoo Finance
How Arcellx (ACLX) Stock Stands Out in a Strong Industry - MSN
ASH ’24: Arcellx Mounts Strong Challenge To Myeloma CAR-T Rival Carvykti - Citeline News & Insights
Arcellx stock target increased, rating held on positive trial data - Investing.com
Arcellx (NASDAQ:ACLX) Receives Buy Rating from Needham & Company LLC - MarketBeat
Arcellx (NASDAQ:ACLX) Price Target Raised to $100.00 - MarketBeat
Arcellx (NASDAQ:ACLX) Price Target Raised to $106.00 at Morgan Stanley - MarketBeat
Robert W. Baird Issues Positive Forecast for Arcellx (NASDAQ:ACLX) Stock Price - MarketBeat
HC Wainwright Increases Arcellx (NASDAQ:ACLX) Price Target to $95.00 - MarketBeat
Gilead, Arcellx Tout Best-in-Class Potential for CAR T Therapy in Multiple Myeloma - BioSpace
Arcellx shares target upgraded, maintains buy on positive trial data By Investing.com - Investing.com South Africa
Arcellx stock target increased, rating held on positive trial data By Investing.com - Investing.com UK
Navigating 7 Analyst Ratings For Arcellx - Benzinga
Arcellx to present positive data on multiple myeloma treatments - PharmaTimes
BofA raises Arcellx price target to $100 on positive data By Investing.com - Investing.com South Africa
BofA raises Arcellx price target to $100 on positive data - Investing.com
Arcellx (NASDAQ:ACLX) Shares Gap DownTime to Sell? - MarketBeat
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study - BioSpace
Cancer cell therapy from Arcellx, Gilead shows promise in early data - BioPharma Dive
Arcellx issues updates on anito-cel clinical trials (NASDAQ:ACLX) - Seeking Alpha
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):